To Investigate the Pharmacokinetics of EPORON® and EPREX® After Subcutaneous Administration in Healthy Male Volunteers

NCT ID: NCT02580006

Last Updated: 2015-10-20

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 42 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-11-30
• Study Completion Date: 2016-03-31

Brief Summary

This Phase I study is to compare pharmacokinetics, safety and pharmacodynamics of EPORON and EPREX after single subcutaneous administration.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

EPORON→EPREX

EPORON PFS(PreFilled Syringe) 4000 IU/0.4 mL(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 1.

And wash out for 4 weeks. EPREX INJ.(Injection) 4000 IU(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 29.

Group Type: EXPERIMENTAL

EPORON

Intervention Type: DRUG

single dose administration subcutaneously

EPREX

Intervention Type: DRUG

single dose administration subcutaneously

EPREX→EPORON

EPREX INJ. 4000 IU(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 1.

And wash out for 4 weeks. EPORON PFS 4000 IU/0.4 mL(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 29.

Group Type: EXPERIMENTAL

EPORON

Intervention Type: DRUG

single dose administration subcutaneously

EPREX

Intervention Type: DRUG

single dose administration subcutaneously

Interventions

EPORON

single dose administration subcutaneously

Intervention Type: DRUG

EPREX

single dose administration subcutaneously

Intervention Type: DRUG

Other Intervention Names

EPORON PFS 4000 IU/0.4 mL (Erythropoietin alfa 4000 IU); EPREX INJ. 4000 IU (Erythropoietin alfa 4000 IU)

Eligibility Criteria

Inclusion Criteria

• Healthy male volunteers between the ages of 19~50 at the time of screening
• Weight between 55.0kg~90.0kg with BMI of 18.0~27.0
• Voluntarily participants who agree to observe the precautions in writing after receiving a complete explanation of this trial

Exclusion Criteria

• History of clinically significant illness related to liver (including viral hepatitis), kidney, nervous system, immune system, respiratory system, endocrine system, cardiovascular system, blood system and tumor as well as mental illness (mood disorder, obsessive-compulsive disorder, etc.)
• Hypersensitivity or clinically significant hypersensitivity to the drug (e.g. aspirin, antibiotics, etc.)
• Those whose results meet more than one of the followings in the screening including re-test; Hemoglobin level below 12g/dL or over 17g/dL, Vitamin B12 level below 200pg/mL, Ferritin level below 21.8ng/mL, Transferrin level below 190mg/dL, Reticulocyte, erythrocytes, platelets or serum potassium level over normal range
• Positive on the HIV antibody, HBsAg, HCV(Hepatitis C Virus) antibody tests
• Those whose vital signs measured in sitting position after resting over 3 minutes meet more than one of the following; Systolic BP below 90mmgHg or over 160mmgHg, Diastolic BP below 50mmgHg or over 100mmgHg, Pulse rate over 100
• History of drug abuse, or tested positive in the urine drug screening
• Administration of EPO(erythropoietin), darbepoetin or other EPO protein supply, immunoglobulin within 3 months from the scheduled first dose
• Hypersensitivity to EPO, darbepoetin or excipient in the test drug or anaphylactic reaction towards iron supplement
• Those who received the following diagnosis within 6 months from the screening; Hemoglobinopathy (e.g., homozygous sickle-cell disease, thalassemia of all kinds), Chronic or uncontrollable inflammatory diseases (e.g., rheumatoid arthritis, systemic erythematosus)
• Those who took any ETC(Ethical) drugs or herbal medicine within 2 weeks, or any OTC(Over-the-counter) drugs or vitamins within a week from the scheduled first dose (However, they may be included as the trial subjects at the discretion of the investigator if other conditions are satisfactory.)
• Those who participated other clinical trials and was administered other drugs within 3 months from the scheduled first dose
• Those who bled over 400mL or donated blood within 8 weeks from the scheduled first dose
• Those who have continued drinking (exceeding 21 units/week, 1 unit = 10g of pure alcohol) or who can't abstain from alcohol during the trial period
• Those who have smoked over 10 cigarettes daily in average for the last 3 months or who can't renounce smoking during the trial period
• Those who have ingested grapefruit or caffeine containing food within 3 days from the scheduled first dose or who can't abstain from the during the trial period.
• Those who are preparing for pregnancy or who do not agree with contraception during the trial period
• Those with peculiar eating habits or who can't have meals provided by the hospital
• Those who are considered inappropriate for the trial by the trial investigator based on the result of clinical laboratory test or due to other reasons

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Dong-A ST Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Kyung-sang Yu, MD, Ph.D

Role: PRINCIPAL_INVESTIGATOR

Clinical Pharmacology Class of Seoul National University College of Medicine / Clinical Pharmacology of Seoul National University Hospital

In-jin Jang, MD, Ph.D

Role: STUDY_DIRECTOR

Clinical Pharmacology Class of Seoul National University College of Medicine / Clinical Pharmacology of Seoul National University Hospital

Hyung-gi Lee, MD, Ph.D

Role: STUDY_DIRECTOR

Clinical Pharmacology Class of Seoul National University College of Medicine / Clinical Pharmacology of Seoul National University Hospital

Ju-yeon Cho, Ph.D

Role: STUDY_DIRECTOR

Clinical Pharmacology Class of Seoul National University College of Medicine / Clinical Pharmacology of Seoul National University Hospital

Seung-hwan Lee, MD, Ph.D

Role: STUDY_DIRECTOR

Seoul National University Hospital Clinical Trials Center / Clinical Pharmacology of Seoul National University Hospital

Locations

Seoul National University Hospital Clinical Trials Center

Seoul, , South Korea

Countries

South Korea

Central Contacts

Kyung-sang Yu, MD, Ph.D

Role: CONTACT

ksyu@snu.ac.kr

82-02-2072-1920

Facility Contacts

Kyung-sant Yu, MD, Ph.D

Role: primary

ksyu@snu.ac.kr

82-02-2072-1920

Other Identifiers

DA3285_SC_I

Identifier Type: -

Identifier Source: org_study_id